Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (54)

2024

  1. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice

    Molecular Therapy, Vol. 32, Núm. 3, pp. 722-733

  2. Oncolytic adenoviruses and immunopeptidomics: a convenient marriage

    Molecular Oncology

  3. The emerging field of viroimmunotherapy for pediatric brain tumors

    Neuro-oncology, Vol. 26, Núm. 11, pp. 1981-1993

2023

  1. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378

2022

  1. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas

    JCI Insight, Vol. 7, Núm. 7

  2. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory

    Molecular Cancer Therapeutics, Vol. 21, Núm. 3, pp. 471-480

  3. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

  4. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 7

2021

  1. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 7

  2. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 4

  3. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

    Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820

  4. Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses

    The Lancet Oncology

2019

  1. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models

    Acta neuropathologica communications, Vol. 7, Núm. 1, pp. 64

  2. GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory

    Neuro-Oncology Advances, Vol. 1, Núm. 1

  3. Localized treatment with oncolytic adenovirus delta-24-RGDOX induces systemic immunity against disseminated subcutaneous and intracranial melanomas

    Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6801-6814

  4. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1

2018

  1. DNX-2401, an oncolytic virus, for the treatment of newly diagnosed diffuse intrinsic pontine gliomas: A case report

    Frontiers in Oncology, Vol. 8, Núm. MAR

  2. Linking inflammation and cancer: The unexpected SYK world

    Neuro-Oncology

  3. Oncolytic virotherapy for gliomas: A preclinical and clinical summary

    Gene Therapy in Neurological Disorders (Elsevier), pp. 357-384

  4. Oncolytic viruses as therapeutic tools for pediatric brain tumors

    Cancers, Vol. 10, Núm. 7